Updated:
Ascletis Pharma Inc.
Ascletis Pharma Inc. was founded to develop innovative therapies for viral hepatitis and metabolic disorders, operating as a dual‑headquarter entity...
Ascletis Pharma Inc.
Ascletis Pharma Inc. was founded to develop innovative therapies for viral hepatitis and metabolic disorders, operating as a dual‑headquarter entity between the United States and China. The firm's pipeline includes multiple clinical‑stage candidates, with a focus on non‑alcoholic steatohepatitis (NASH) and chronic hepatitis B. Its Hong Kong Exchange listing (stock code: 1672) provides a public window into its R&D expenditures and partnering activity. The firm allocates capital across internal discovery programs, licensed compounds, and co‑development agreements. Its portfolio includes the fatty acid synthase inhibitor TVB‑2640, licensed from Sagimet Biosciences, and ASC09, an HIV protease inhibitor evaluated for COVID‑19. Therapeutic areas cover fibrosis, cancer, and infectious disease, with assets at Phase I, Phase II, and Phase III stages. Operations span China, the US, and select Asian markets. Ascletis maintains three offices: Menlo Park as its US base, plus Shenzhen and Hangzhou, which support clinical operations and regulatory affairs. Publicly available employment data is limited, but the firm reports headcount in regulatory filings. No separate philanthropic, real‑asset, or investment‑management vehicles have been disclosed. What distinguishes Ascletis is its hybrid structure as a publicly‑traded biopharma with treasury management functions that resemble those of a corporate venture arm. The listed entity serves as both operating company and capital allocator, deploying cash from public markets and partnered licensing into internal R&D and external biotech assets. Its Hong Kong exchange presence provides quarterly scrutiny uncommon among private family‑office biotech shops.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Menlo Park
Corporate office
Menlo Park, CA, United States
Additional offices
Shenzhen · Hangzhou
Sector focus
Frequently asked questions
Who runs clinical development at Ascletis Pharma?
In 2025, Ascletis restructured its senior management with Dr. Jinzi J. Wu as CEO. The R&D pipeline is overseen by executives with backgrounds at major pharma firms including Roche and GSK. Day‑to‑day strategy for the NASH and hepatitis B programs is driven by a China‑based clinical team (public record).
Does Ascletis license its pipeline or co‑develop with partners?
Yes. The firm's fatty acid synthase program for NASH was licensed from Sagimet Biosciences (formerly 3-V Biosciences). Co‑development agreements have included collaborations with academic centers in China for clinical trials. International partnerships for ex‑China rights are a known part of the business model.
How does Ascletis allocate its cash and treasury?
As a publicly traded entity, Ascletis raises capital through equity offerings and partnerships, deploying cash into internal R&D, licensing fees, and clinical manufacturing. The firm does not maintain a separate asset management division, but its treasury function actively manages cash for operating needs and pipeline advancement (per annual reports).
What therapeutic areas does Ascletis target?
The firm prioritizes chronic hepatitis B, non‑alcoholic steatohepatitis (NASH), and oncology. Metabotropic drug candidates for fibrosis and metabolic disorders are also in the mix. HIV and COVID‑19 programs have been suspended or deprioritized.
Is Ascletis structured more as a family office or a pharmaceutical firm?
Ascletis is a publicly listed biopharmaceutical company, not a family office. Its capital allocation bears similarities to a corporate venture entity managing a single‑asset pipeline, but it operates with full clinical development and commercial infrastructure. No family‑office structure or multi‑generation wealth management component has been disclosed.
What is Ascletis's geographic footprint beyond the US?
The firm operates clinical sites and regulatory functions in Shenzhen and Hangzhou, China. Its Menlo Park office supports US operations and investor relations. The Hong Kong exchange listing provides access to Asian capital markets.
Has Ascletis disclosed any sustainability or ESG policies?
No specific ESG framework or publicly filed sustainability report was found. The firm's Hong Kong exchange listing may require ESG disclosures, but none were published as of early 2026.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: